SYNOPSIS

Review of “Extended interval BNT162b2 vaccination enhances peak antibody generation in older people”

05/26/2021


One-minute summary

- This is a population-based cohort study evaluating the relative immunogenicity of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination when comparing a standard versus extended interval between vaccine doses in the two-dose regimen.

- Immunogenicity was measured two weeks after administration of the second dose and compared for those who have received a standard interval (3 weeks) to those who have received an extended interval (11 to 12 weeks) between doses.

- The study included 172 participants over the age of 80 years identified from primary care networks in Birmingham, United Kingdom (UK). The standard interval was provided to 99 participants and the extended interval was provided to 73 participants. However, after exclusion of patients who had evidence of prior COVID-19, there were 89 and 68 patients in the standard and extended interval groups, respectively.

- The authors found that following two doses of the BNT162b2 Pfizer-BioNTech COVID-19 vaccine, both regimens produced high antibody responses; however, the extended interval was associated with a 3.5-fold higher spike-protein specific antibody response. Conversely, the extended interval was associated with a 3.6-fold lower cell-mediated immune response.

Additional information

- Median age of participants was 84 years in both groups (standard interval, interquartile range [IQR]: 80–87; extended interval, IQR: 82–89).

- Humoral immunity: IgG, IgA, IgM antibodies specific to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were detected using an electrochemiluminescence assay. Antinucleocapsid protein antibodies and anti-spike protein antibodies were measured.
• **Cell-mediated immunity**: Interferon gamma ELISPOT analysis was used to determine SARS-CoV-2 spike (S)-specific T cell responses. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples. PBMCs were plated into wells of the T-SPOT Discovery SARS-CoV-2 Kit containing four different peptide pools representing SARS-CoV-2 antigens, including positive and negative controls. PBMCs were incubated and interferon-gamma-secreting T cells were counted.

• Two venipuncture blood samples were drawn from each patient to assess peak antibody responses 2-3 weeks following the second dose of the vaccine. Participants had blood drawn at the same time points at 5-6 weeks and 13-14 weeks following the first vaccine, for comparative purposes:
  
  **Standard Interval Schedule**:
  1. 2-3 weeks after second dose (5–6 weeks after first dose, to assess peak response in standard interval); and
  2. 8-9 weeks after second dose (13-14 weeks after first dose, to assess durability in the response).

  **Extended Interval Schedule**:
  1. 5-6 weeks after first dose; and
  2. 2-3 weeks after second dose (13–14 weeks following the first dose, to assess peak response in extended interval).

• **Humoral immunity** – Spike-specific antibodies:
  
  **Detectability**
  
  ▪ **Standard interval**: were detected in 100% of participants at both time-points (first sample: 86/86; second sample: 79/79).
  
  ▪ **Extended interval**: were detected in 91% (62/68) at 5–6 weeks after the first dose and 100% (55/55) at 2–3 weeks after the second dose.

  **Magnitude**
  
  ▪ **Standard interval**: median antibody titre peaked at 1,138 Units per mL (U/mL) after second dose (peak) (2.6-fold decrease; p<0.0001).
  
  ▪ **Extended interval**: median antibody titre was at 17 U/mL at 5–6 weeks after first vaccine dose and 4,030 U/mL after second dose (peak) (242-fold increase; p<0.0001).

• **Cell-mediated immunity** – Spike-specific T cell responses (interferon-gamma analysis)
  
  **Detectability**
  
  ▪ **Standard interval**: 60% (53/89) had cellular response at 2–3 weeks following second vaccine dose (peak) and 15% (12/79) had cellular response 8–9 weeks later.
  
  ▪ **Extended interval**: 8% (6/67) demonstrated cellular response at 5–6 weeks following the first dose and 31% (17/55) had cellular response 2–3 weeks following the second vaccine dose (peak).

  **Magnitude**
  
  ▪ **Standard Interval**: 72 spots/million PBMC at 2–3 weeks following second vaccine dose (peak), then 24 spots/million PBMC after 8–9 weeks (3-fold decrease; p<0.0001).
  
  ▪ **Extended interval**: 8 spots/million PBMC at 5–6 weeks after the first vaccine, followed by 20 spots/million PBMC 2–3 weeks following the second dose (peak) (2.5-fold increase; p<0.0001).
• In the few patients that had prior natural infection (who were excluded from the primary analysis), previous infection strongly enhanced vaccine response:
  - **Standard Interval**: median peak antibody responses of 32,250 U/mL (n=10), decreasing by 3.5-fold over the subsequent 8 weeks.
  - **Extended Interval**: median peak antibody response 90,750 U/mL (n=2).

**PHO reviewer’s comments**

• These data confirm previous findings that a standard interval elicits strong antibody responses in those over the age of 80 years, but suggests waning humoral immunity over the subsequent two months after the second vaccine dose administration.

• Although the BNT162b2 (Pfizer-BioNTech) vaccine is authorized for administration of two doses with the interval of three weeks between doses, several jurisdictions, including Ontario, have chosen to administer the second dose after 16 weeks in order to increase the rate of first-dose vaccine coverage across the population. These preliminary findings provide reassurance that such an approach may provide reasonable protection in older adults, especially after the second dose is received.

• SARS-CoV-2 spike-specific antibodies were 3.5-fold higher following the second dose of the vaccine in the extended interval patients compared to those receiving the standard interval, but longitudinal data are needed to confirm whether this translates to additional or prolonged protection. Further, this study is limited by the lack of immunogenicity data 8-9 weeks after the second vaccine dose in those receiving an extended interval schedule.

• Since the importance of cellular immunity in protection against SARS-CoV-2 is not clear and participants receiving the extended interval regimen appeared to have lower cell-mediated immune responses, the impact of these regimens on actual protection against COVID-19 requires confirmation in clinical studies.

• This study is published as a pre-print, it has not been peer-reviewed and as such the findings should be interpreted with caution.